Each year, an estimated 3.6 million episodes of RVGE occur among the 23.6 million children under 5 years of age in the European Union.1 Yet early vaccination can provide a high degree of protection for infants before the peak incidence of the disease.
Prof. Dr. Timo Vesikari, University of Tampere, Finland, lead author for the European recommendations commented, “Rotavirus affects almost all young children causing severe diarrhoea and vomiting. In the most severe cases, infants may need to be hospitalised. This causes a considerable burden on hospitals where it can spread rapidly through paediatric wards. We convened a group of experts to address the rotavirus issue and have concluded that to effectively reduce the burden of rotavirus gastroenteritis in Europe, universal vaccination of infants is recommended. The vaccines available are effective, have a good safety profile and can fit in with existing national vaccine schedules.”
“This recommendation for universal vaccination against rotavirus is very good news for European infants, their parents and hospitals,” said Jean Stéphenne, president of GSK Biologicals. “Rotavirus vaccination can provide a high degree of protection against rotavirus disease and its distressing symptoms that many children suffer. Fortunately, not many children die in Europe from rotavirus infection, but the burden on healthcare resources needed in treating outbreaks of the disease is very high and the vaccine will resolve major issues for paediatric hospitals.”
Rotavirus is the primary cause of acute gastroenteritis (diarrhoea and vomiting) leading to hospitalisation of infants and young children. New evidence presented today at the ESPID annual meeting shows that the burden of disease may be even higher than previously described. A study conducted in French, German, Italian, Spanish and UK hospitals investigated the burden of RVGE in children under 5 years of age over a 19-month period.2 The results show that rotavirus accounts for 56.2% of hospitalisations due to acute gastroenteritis. RVGE is more common in younger children, with a majority of cases occurring in children under 2 years and 18% of cases occurring in infants less than 6 months of age.2 Previous studies have reported that the duration of hospitalisation is longest in the youngest infants, particularly those who are under 4 months of age.3
Vaccination is the most effective way to provide a high level of protection for young children against RVGE.4,5 New data announced at the ESPID congress show that Rotarix™ provides sustained protection in children against RVGE up to the age of 2 years.6 Given in a convenient two-dose schedule, the oral vaccine offers early protection, before the peak incidence of the disease at 6-24 months.7 Rotarix™ prevents 96% of hospitalisations due to RVGE and reduces the need for medical attention by 84%.6 Principle investigator, Prof. Dr. Timo Vesikari, commented, “The new data substantiate the evidence for Rotarix™ showing that the vaccine’s efficacy is proven over the first two years of life which is the most vulnerable period to suffer from severe rotavirus gastroenteritis.”
Luke Willats | alfa
Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg
New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences